Cancer BiologybioRxivPreprint
The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations.
J. Kim, F. Cai, B. Ko…·R. J. DeBerardinis
The paper identifies the hexosamine biosynthesis pathway as a metabolic vulnerability in KRAS/LKB1 mutant lung cancers and shows GFPT2 inhibition reduces tumor growth.